晚期前列腺癌采用內(nèi)分泌藥物治療的療效觀察

孫維

【摘要】 目的 分析對于晚期前列腺癌患者， 采用內(nèi)分泌藥物治療的臨床效果。方法 選擇行手術(shù)治療的晚期前列腺癌患者100例， 根據(jù)術(shù)后給予內(nèi)分泌藥物不同分為A組、B組， 每組50例， A組術(shù)后給予比卡魯胺， B組術(shù)后給予氟他胺;選擇同期單純實施手術(shù)治療的50例患者作為對照組， 術(shù)后不給予內(nèi)分泌藥物治療。比較三組患者臨床癥狀緩解情況及治療前后前列腺特異抗原（PSA）水平、前列腺體積， 隨訪1年復(fù)發(fā)情況。結(jié)果 治療后， A組患者臨床癥狀緩解率為80.00%;B組患者臨床癥狀緩解率為82.00%;對照組患者臨床癥狀緩解率為60.00%。A組、B組患者的臨床癥狀緩解率均明顯高于對照組， 差異具有統(tǒng)計學(xué)意義（P<0.05）;A組、B組患者的臨床癥狀緩解率比較， 差異無統(tǒng)計學(xué)意義（P>0.05）。治療后， A組、B組患者的PSA水平均低于對照組， 差異有統(tǒng)計學(xué)意義（P<0.05）;A組、B組患者的PSA水平比較差異無統(tǒng)計學(xué)意義（P>0.05）。隨訪1年， A組出現(xiàn)生化復(fù)發(fā)5例， 復(fù)發(fā)率為10.00%;B組出現(xiàn)生化復(fù)發(fā)6例， 復(fù)發(fā)率為12.00%;對照組出現(xiàn)生化復(fù)發(fā)14例， 復(fù)發(fā)率為28.00%。A組、B組患者的復(fù)發(fā)率均低于對照組， 差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后， 三組患者前列腺體積均小于本組治療前， 差異具有統(tǒng)計學(xué)意義（P<0.05）;三組患者前列腺體積比較差異無統(tǒng)計學(xué)意義（P>0.05）。結(jié)論 晚期前列腺癌患者術(shù)后給予比卡魯胺以及氟他胺治療的效果較為理想， 可以降低復(fù)發(fā)率， 改善患者術(shù)后情況。

【關(guān)鍵詞】 晚期前列腺癌;內(nèi)分泌藥物;療效

【Abstract】 Objective? ?To analyze the clinical effect of endocrine drug therapy for patients with advanced prostate cancer. Methods? ?A total of 100 patients with advanced prostate cancer undergoing surgical treatment were divided into group A and group B according to different endocrine drugs given after operation， with 50 cases in each group. Group A was treated with bicalutamide， and group B was treated with flutamide. 50 patients who underwent surgery alone at the same time were selected as control group， and no endocrine drugs were given after operation. Comparison was made on remission status of clinical symptoms， prostate specific antigen （PSA） level and prostate volume before and after treatment， and recurrence status after 1-year follow-up between the two groups. Results? ?After treatment， the remission rate of clinical symptoms was 80.00% in group A， and that was 82.00% in group B and 60.00% in the control group. The remission rate of clinical symptoms in group A and group B was obviously higher than that in the control group， and the difference was statistically significant （P<0.05）. There was no statistically significant difference in remission rate of clinical symptoms in group A and group B （P>0.05）. After treatment， the PSA level in group A and group B was lower than that in the control group， and the difference was statistically significant （P<0.05）. There was no statistically significant difference in PSA level in group A and group B （P>0.05）. After 1-year follow-up， there was 5 cases of biochemical recurrence in group A， with recurrence rate as 10.00%; 6 cases of biochemical recurrence in group B， with recurrence rate as 12.00%; 14 cases of biochemical recurrence in the control group， with recurrence rate as 28.00%. The recurrence rate in group A and group B was lower than that in the control group， and the difference was statistically significant （P<0.05）. After treatment， the prostate volume in three groups was smaller than those before treatment， and the difference was statistically significant （P<0.05）. There was no statistically significant difference in prostate volume in three groups （P>0.05）. Conclusion? ?Bicalutamide and flutamide shows ideal effect for patients with advanced prostate cancer， and it can reduce the recurrence rate and improve the postoperative condition of patients.